ADMA Biologics reported third quarter 2025 revenue of $134.2 million, up 12% year over year, with GAAP net income...

EyePoint Pharmaceuticals has fully enrolled its two Phase 3 trials in wet age-related macular degeneration (LUGANO and LUCIA), initiated...

MoonLake Immunotherapeutics reported third-quarter 2025 results and a cascade of clinical updates that set up sonelokimab for a pivotal...

Inotiv reported fourth-quarter fiscal 2025 revenue of $138.1 million, up 5.9% year over year, and full-year revenue of $513.0...

BioCryst Pharmaceuticals received early termination of the Hart-Scott-Rodino waiting period for its proposed acquisition of Astria Therapeutics, clearing a...

OKYO Pharma’s executive chairman, through an affiliated entity, has increased his stake in the company by purchasing 27,051 additional...

Catalyst Pharmaceuticals posted third-quarter 2025 revenue of $148.4 million, up 17% year over year, and raised full-year guidance to...

NeuroThera Labs, the clinical-stage subsidiary majority-owned by SciSparc, has signed a non-binding term sheet to acquire a 55% stake...

Kura Oncology has recorded the first U.S. commercial sale of Komzifti (ziftomenib), its once-daily oral menin inhibitor approved on...

NewgenIVF Group reported a sharp swing to profitability for the first nine months of 2025, posting $17.5 million in...